Drug Profile
ISV 616
Latest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator InSite Vision
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetic retinopathy; Macular degeneration
Most Recent Events
- 20 Aug 2003 This compound is still in active development
- 10 Sep 2001 Preclinical development for Diabetic retinopathy in USA (Ophthalmic)
- 10 Sep 2001 Preclinical development for Macular degeneration in USA (Ophthalmic)